NTHL1 and cancer: To examine the cancer risks for the heterozygous carriers, we retrieved the results for additive risk association analyses from FinnGen for the available malignant tumour types, which have been diagnosed in the patients with biallelic NTHL1 variants in the FinnGen data or reported previously6–11,13.